Pharming Reports on Annual General Meeting of Shareholders
Financial updates
Pharming Group reports financial results for the first quarter of 2021
Financial updatesPharming Group N.V. presents its (unaudited) financial report for the first quarter of the year ended 31 March 2021.
Pharming Group announces the filing of its 2020 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
Financial updatesPharming Group announces the filing of its Annual Report on Form 20-F for the year ended 31 December 2020 with the U.S. Securities and Exchange Commission (SEC)
Pharming Group announces the publication of its 2020 Annual Report and convenes its 2021 AGM
Financial updatesPharming Group N.V. announces the publication of its Annual Report for the year ended 31 December 2020. In addition, the Company’s 2021 Annual General Meeting (AGM) will be held at 16:00CET on Wednesday, 19 May 2021. The Notice to Convene, Explanatory Notes, meeting documents and Form of Proxy can be found on the Company’s website, under Investors/Shareholders’ Meetings.
Pharming Group reports financial results for full year 2020
Financial updatesPharming Group N.V. presents its preliminary (unaudited) financial report for the full year ended 31 December 2020.
Pharming Group announces ADSs admitted to trade on Nasdaq under the symbol “PHAR”
Financial updatesPharming Group announces that, effective today, its American Depositary Shares (“ADSs”) have been admitted for listing on the Nasdaq Global Market (“Nasdaq”) under the symbol “PHAR” and will begin trading tomorrow; Wednesday 23 December. Each ADS represents 10 of the Company’s ordinary shares of €0.01 nominal value (“Ordinary Shares”).
Pharming Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq Listed ADSs
Financial updatesCosts for conversion of Ordinary Shares into ADS’s waived by JP Morgan Chase for initial four weeks after today
Pharming Reports on Extraordinary General Meeting of Shareholders
Financial updatesPharming Group N.V. announces that at its Extraordinary General Meeting of shareholders (EGM), held today, all proposals were approved. As a result, the one-tier board structure has become effective, and Barbara Yanni and Mark Pykett have been appointed as non-executive board members.
Pharming Group Publicly Files Registration Statement with the U.S. SEC to Facilitate Listing of ADSs Representing Ordinary Shares on Nasdaq Global Market
Financial updatesPharming Group N.V., a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs, today announces that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (the "SEC") in connection with a proposed listing of American Depositary Shares ("ADSs") representing the Company's ordinary shares of nominal value €0.01 each ("Ordinary Shares") on the Nasdaq Global Market ("Nasdaq").
Pharming convenes Extraordinary General Meeting of shareholders
Financial updatesPharming Group N.V. announces it will hold an Extraordinary General Meeting (EGM) of Shareholders on Friday 11 December 2020 at 14:00 CET.